Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor
Authors:
- Vittorio PerfettiVPVittorio Perfetti
- Giovanni PalladiniGiovanni Palladini
- Laura BrunettiLBLaura Brunetti
- Adele SgarellaASAdele Sgarella
- Silvia BrugnatelliSBSilvia Brugnatelli
- Paolo G. GobbiPGPaolo G. Gobbi
- Gino Roberto CorazzaGCGino Roberto Corazza
- 1 July 2007
- journal article
- case report
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 19 (7) , 599-601
Abstract
Bortezomib is the first anticancer proteasome inhibitor introduced into clinical practice. It has been recently approved for the treatment of multiple myeloma, an incurable plasma cell tumour that accounts for 10-15% of all haematologic malignancies and for approximately 20% of deaths. Gastrointestinal toxicity associated with the use of this drug is common but generally mild to moderate. Paralytic ileus in patients undergoing bortezomib treatment has been reported, although a definite attribution to bortezomib administration has not been established. We report a myeloma patient who developed severe paralytic ileus during bortezomib therapy, which presented in the context of progressive constipation without other known causes and which regressed promptly with medical management after drug cessation, suggesting a direct causal relationship. Awareness of the various potential gastrointestinal toxic effects of bortezomib is of relevance given the growing number of patients undergoing treatment with this important and effective new cancer drug.Keywords
This publication has 11 references indexed in Scilit:
- Bortezomib: efficacy comparisons in solid tumors and hematologic malignanciesNature Clinical Practice Oncology, 2006
- A Practical Update on the Use of Bortezomib in the Management of Multiple MyelomaThe Oncologist, 2006
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapyCancer Cell International, 2005
- Bortezomib-Induced Severe Hepatitis in Multiple MyelomaArchives of internal medicine (1960), 2005
- Proteasome Inhibition As a Novel Therapeutic Target in Human CancerJournal of Clinical Oncology, 2005
- Multiple MyelomaNew England Journal of Medicine, 2004
- Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine TumorsClinical Cancer Research, 2004
- A Phase 2 Study of Bortezomib in Relapsed, Refractory MyelomaNew England Journal of Medicine, 2003
- The proteasome: structure, function, and role in the cellCancer Treatment Reviews, 2003